U.S. Markets close in 5 hrs

A Look at Sarepta’s Exondys 51 Commercialization Efforts

Kenneth Smith
A Look at Sarepta’s Exondys 51 Commercialization Efforts

By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders. The company’s first product on the US market, the Exondys 51 injection, received accelerated approval from the US FDA in September 2016. The injection is targeted for treating Duchenne muscular dystrophy (or DMD).